{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=74", "query": { "condition": "Relapsed/Refractory", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=75&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=73&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T19:42:49.035Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03345485", "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Soft Tissue Sarcoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Tinostamustine 60mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 100mg/m2 over 30min", "type": "DRUG" }, { "name": "Tinostamustine 60mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 100mg/m2 over 60min", "type": "DRUG" }, { "name": "Tinostamustine 80mg/m2 over 80min", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mundipharma Research Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-11-08", "completion_date": "2023-03-29", "has_results": true, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03345485" }, { "nct_id": "NCT04730349", "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ependymoma", "Ewing Sarcoma", "High-grade Glioma", "Leukemia and Lymphoma", "Medulloblastoma", "Miscellaneous Brain Tumors", "Miscellaneous Solid Tumors", "Neuroblastoma", "Relapsed, Refractory Malignant Neoplasms", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "NKTR-214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 15, "start_date": "2021-06-03", "completion_date": "2022-06-22", "has_results": true, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • St Louis, Missouri", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04730349" }, { "nct_id": "NCT07284758", "title": "A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Cemsidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-02-18", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 25, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284758" }, { "nct_id": "NCT02891278", "title": "Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Sertraline", "type": "DRUG" }, { "name": "Cytosine arabinoside", "type": "DRUG" }, { "name": "allogeneic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2016-08-11", "completion_date": "2020-11-17", "has_results": false, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02891278" }, { "nct_id": "NCT00510887", "title": "Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2007-01", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-05-12", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00510887" }, { "nct_id": "NCT04890093", "title": "Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sarcoma, Ewing", "Rhabdomyosarcoma" ], "interventions": [ { "name": "PEN-866", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Years to 39 Years" }, "enrollment_count": 64, "start_date": "2024-10-31", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04890093" }, { "nct_id": "NCT01652014", "title": "Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652014" }, { "nct_id": "NCT00964821", "title": "Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm" ], "interventions": [ { "name": "trivalent influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Immunoenzyme technique", "type": "OTHER" }, { "name": "Laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 459, "start_date": "2007-01", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2017-11-07", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964821" }, { "nct_id": "NCT03374332", "title": "Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Gemtuzumab Ozogamicin (GO)", "type": "DRUG" }, { "name": "Donor Leukocytes", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-12-31", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374332" }, { "nct_id": "NCT01499147", "title": "Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Leukemia", "Chronic Myelogenous Leukemia", "Malignant Lymphoma", "Hodgkin's Disease", "Multiple Myeloma", "Lymphocytic Leukemia", "Myeloproliferative Disorder", "Polycythemia Vera", "Myelofibrosis", "Aplastic Anemia" ], "interventions": [ { "name": "fludarabine/busulfan", "type": "DRUG" }, { "name": "fludarabine/ melphalan", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2000-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2018-11-08", "last_synced_at": "2026-11-14T19:42:49.035Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499147" } ] }